<DOC>
	<DOCNO>NCT01932372</DOCNO>
	<brief_summary>The objective Surveillance verify follow subject matter concern Tofacitinib ( Xeljanz ) general practice . 1 ) Occurrence adverse reaction , factor may potentially affect safety efficacy 2ï¼‰ Long-term safety ( particularly , malignant tumor serious infection ) efficacy Occurrences malignant tumor serious infection compare control group .</brief_summary>
	<brief_title>Tofacitinib ( Xeljanz ) Special Investigation Rheumatoid Arthritis</brief_title>
	<detailed_description>All patient investigator prescribes Xeljanz Standard Care rheumatoid arthritis register consecutively number subject reach target number order extract patient enrol investigation random .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>All patient receive Tofacitinib ( Xeljanz )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Good Post Marketing Study Practice</keyword>
	<keyword>Tofacitinib</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
</DOC>